Realm Therapeutics Provides Clinical Update, including Results from a Phase 2 Study of PR013 in Allergic Conjunctivitis
- Monday, March 12, 2018, 6:19
- Environment
- Add a comment
MALVERN, Pa., March 12, 2018 /PRNewswire/ — Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today provides an update on the Company’s clinical programs.
The Company reports that…
Source: https://www.prnewswire.com/news-releases/realm-therapeutics-provides-clinical-update-including-results-from-a-phase-2-study-of-pr013-in-allergic-conjunctivitis-300612160.html
About the Author
adminasapcorp has written 39391 stories on this site.